Edgewise Therapeutics (EWTX) Interest & Investment Income (2020 - 2026)

Edgewise Therapeutics has disclosed Interest & Investment Income across 7 years of filings, most recently posting $5.1 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $5.1 million, down 1.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.6 million (down 1.67% YoY), and the FY2025 annual result was $23.6 million, down 5.63% from the prior year.
• Interest & Investment Income came in at $5.1 million for Q1 2026 at Edgewise Therapeutics, down from $5.8 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.6 million in Q2 2024 to a low of $166000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $5.1 million (2026), against an average of $4.2 million.
• Across the five-year window, Interest & Investment Income surged 2014.29% in 2022 and slipped 17.13% in 2025, its largest moves.
• Edgewise Therapeutics' Interest & Investment Income stood at $2.7 million in 2022, then surged by 39.6% to $3.7 million in 2023, then surged by 58.05% to $5.9 million in 2024, then fell by 1.96% to $5.8 million in 2025, then retreated by 11.47% to $5.1 million in 2026.
• The last three Interest & Investment Income figures came in at $5.1 million (Q1 2026), $5.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.